---
company: Evolent Health, Inc.
ticker: EVH
form: 8-K
filed: 2026-05-07
accession: 0001628908-26-000031
source: https://www.sec.gov/Archives/edgar/data/1628908/000162890826000031/
---

# Evolent Health (EVH) earnings release, May 7, 2026

Evolent Health, Inc. (EVH) · Form 8-K, Item 2.02 · Filed 2026-05-07 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1628908/000162890826000031/)

Evolent Announces First Quarter 2026 Results

WASHINGTON (May 7, 2026) – Evolent Health, Inc. (NYSE: EVH) (“Evolent” or the “Company”), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended March 31, 2026.

Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, “I am happy with the strong start to the year. We are on track with our plan and have had successful, on-time oncology launches at both Highmark and Aetna. As we look into 2027 and beyond, we remain focused on both extending our market leadership in oncology and addressing the big opportunity we have with AI, all while fulfilling our commitments to shareholders, employees and customers.”

Highlights for the three months ended March 31, 2026 include (dollars in thousands, except for average PMPM fees and revenue per case):

The rising medical costs impacting health plans continue to drive robust demand for Evolent’s complex specialty care solutions.¹

Evolent announced two new revenue agreements:

• An existing Performance Suite client has signed a contract for our advanced imaging solution, which is expected to go live in the third quarter, subject to state regulatory approvals in certain states, with approximately 4.5 million lives across the Commercial, Medicaid and Medicare lines of business.

• In the Performance Suite, one of our national payer clients is expanding their line‑of‑business reach of our existing Oncology and Cardiology solution into several new markets across the Commercial and Medicare lines of business. This expansion is expected to generate over $200 million of annual revenue and is scheduled to go live in the third quarter subject to regulatory approvals in certain states.

Financial Results of Evolent Health, Inc.

In our earnings releases, prepared remarks, conference calls, slide presentations and webcasts, we may use or discuss financial measures not prepared in accordance with generally accepted accounting principles (“GAAP”). Definitions of the non-GAAP financial measures as well as reconciliations of non-GAAP financial measures to the most directly comparable GAAP financial measures are presented herein. See “Non-GAAP Financial Measures” for more information.

Reported Results

Evolent Health, Inc. reported the following results in accordance with GAAP (dollars in thousands, except for per share data):

Total cash and cash equivalents was $142.0 million as of March 31, 2026.

Adjusted Results

Evolent Health, Inc. reported the following adjusted results (dollars in thousands, except for per share data):²

Business Outlook

The Company does not believe it can meaningfully reconcile guidance for non-GAAP Adjusted EBITDA to net income (loss) attributable to common shareholders of Evolent Health, Inc. because the Company cannot provide guidance for the more significant reconciling items between net income (loss) attributable to common shareholders of Evolent Health, Inc. and Adjusted EBITDA without unreasonable effort. This is due to the fact that future period non-GAAP guidance includes adjustments for items not indicative of our core operations, and as a result from changes to our business due to transactions and other events. Such items may, from time to time, include change in tax receivable agreement liability, other refinancing fees, gain (loss) from equity method investees, gain (loss) on repayment/extinguishment of debt, other income (expense), gain (loss) on disposal of non-strategic assets, goodwill impairments, right-of-use asset impairments, gain (loss) on lease terminations, stock-based compensation expense, severance costs and transaction-related costs. Such adjustments may be affected by changes in ongoing assumptions, judgments, as well as nonrecurring, unusual or unanticipated charges, expenses or gains (losses) or other items that may not directly correlate to the underlying performance of our business operations. The exact amount of these adjustments is not currently determinable but may be significant.

Full Year 2026 Guidance

Incorporating its year-to-date performance, the Company is reiterating its 2026 revenue guidance range of $2.4 billion to $2.6 billion and Adjusted EBITDA range of approximately $110 million to $140 million, respectively.

Additional Outlook Information

The Company expects to deploy approximately $25 million to $30 million in cash for capitalized software development during 2026.

This “Business Outlook” section contains forward-looking statements, and actual results may differ materially. Factors that may cause actual results to differ materially from our current expectations in addition to those set forth above are set forth below in “Forward Looking Statements - Cautionary Language” and Evolent Health, Inc.'s filings with the Securities and Exchange Commission (“SEC”).

Web and Conference Call Information

Evolent Health, Inc. will hold a conference call to discuss its financial performance and related matters this morning, May 7, 2026, at 8:00 a.m., Eastern Time. To listen to a live broadcast via the internet and view the accompanying materials, please visit the Company's Investor Relations website at http://ir.evolent.com. To participate by telephone, dial (855) 940-9467, or (412) 317-6034 for international callers, and ask to join the “Evolent Health call.” Participants are advised to dial in at least fifteen minutes prior to the call to register. The call will be archived on the Company's website for one week and will be available beginning later this evening. Evolent invites all interested parties to attend the conference call.

About Evolent... (truncated)s and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting evolent.com.

Contacts: investorrelations@evolent.com

Definitions

Revenue Agreements

Evolent reports the number of new revenue agreements signed for Performance Suite, Specialty Technology and Services Suite, Administrative Services and Case-based products. A new revenue agreement includes incremental revenue to the Company reflecting contracts for services to both new partner entities, corporations or health plans as well as additional sales to existing partners. New revenue agreements may include incremental services, geographic, or line of business³ expansions or a combination thereof. The conversion of Specialty Technology and Services Suite contracts to Performance Suite are also included in this definition. The Company does not count renewals for existing scope, growth of membership within an existing contract scope or transaction-related purchase agreements, if applicable, in this metric.

Lives on Platform and Per Member Per Month (“PMPM”) Fee

Performance Suite Lives on Platform are calculated by summing monthly members covered for specialty care services for contracts not under ASO arrangements, plus members managed by Complex Care in capitation arrangements and divided by the number of months in the period. Specialty Technology and Services Suite Lives on Platform are calculated by summing monthly members covered for oncology, cardiology, musculoskeletal, advanced imaging and other diagnostic specialty care services for contracts under ASO arrangements divided by the number of months in the period. Administrative Services Lives on Platform are calculated by summing monthly members covered for administrative services implementation and core performance services divided by the number of months in the period. Cases are calculated by summing the number of individuals receiving services through our surgery management and advanced care planning programs in a given period. Members covered for more than one category are counted in each category.

Performance Suite Average PMPM fee is defined as revenue pertaining to our Performance Suite during the period reported divided by Performance Suite Lives on Platform for the period divided by the number of months in the period. Specialty Technology and Services Suite Average PMPM fee is defined as revenue pertaining to the Specialty Technology and Services Suite during the period reported divided by Specialty Technology and Services Suite Lives on Platform for the period divided by the number of months in the period. Administrative Services Average PMPM fee is defined as revenue pertaining to the Administrative Services during the period reported divided by the Administrative Services Lives on Platform for the period divided by the number of months in the period. Revenue per Case is calculated by the revenue pertaining to surgery management and advanced care planning programs divided by the number of cases for a given period.

Average Unique Members are calculated by summing members covered by our Performance Suite, Specialty Technology and Services Suite and Administrative Services. In cases where partners cross between multiple solutions, we only capture members from the solution with the maximum number of members.

Management uses Lives on Platform, PMPM fees, Cases, Revenue per Case and Average Unique Members because we believe that they provide insight into the unit economics of our services. We believe that these measures are also useful to investors because they allow further insight into the period over period operational performance.

Medical Expense Ratio

Medical Expense Ratio (“MER”) is a key performance indicator used by management for purposes of monitoring operating performance and is calculated as GAAP total claims incurred related to our specialty care management services solution divided by GAAP revenue related to our Performance Suite. Management believes MER is useful to investors because it provides insight into the efficiency with which medical costs are managed relative to revenue and helps identify trends in the underlying performance. For periods prior to the consummation of the sale of Evolent Care Partners (“ECP”) in December 2025, we present non-GAAP MER excluding revenues from ECP because is not indicative of ongoing operations.⁴

## Financial statements

### Income Statement (For the Three Months Ended March 31, — Highlights for the three months ended March 31, 2026 include (dollars in thousands, except for average PMPM fees and revenue per case):)

| | For the Three Months Ended March 31, – 2026 | 2025 |
|---|---:|---:|
| Financial Results: | Revenue | 496,246 | 483,649 |
| Financial Results: | Net loss attributable to common shareholders of Evolent Health, Inc. | -26,632 | -72,250 |
| Financial Results: | Net loss margin | -5.4 | -14.9 |
| Financial Results: | Adjusted EBITDA | 22,067 | 36,860 |
| Financial Results: | Adjusted EBITDA Margin | 4.4 | 7.6 |
| Average Lives on Platform/Cases | Performance Suite | 6,078 | 6,486 |
| Average Lives on Platform/Cases | Specialty Technology and Services Suite | 76,101 | 77,079 |
| Average Lives on Platform/Cases | Administrative Services | 1,118 | 1,213 |
| Average Lives on Platform/Cases | Cases | 11 | 14 |
| Average Lives on Platform/Cases | Average Unique Members | 38,903 | 40,628 |
| Average PMPM Fees/ Revenue per Case | Performance Suite | 17.73 | 15.57 |
| Average PMPM Fees/ Revenue per Case | Specialty Technology and Services Suite | 0.35 | 0.36 |
| Average PMPM Fees/ Revenue per Case | Administrative Services | 14.78 | 15.72 |
| Average PMPM Fees/ Revenue per Case | Cases | 3,772 | 2,947 |
| Average PMPM Fees/ Revenue per Case | Medical Expense Ratio | 93.3 | 68 |
| Average PMPM Fees/ Revenue per Case | Medical Expense Ratio excluding Evolent Care Partners | 93.3 | 84 |

### Income Statement (For the Three Months Ended March 31, — Evolent Health, Inc. reported the following results in accordance with GAAP (dollars in thousands, except for per share data):)

| | For the Three Months Ended March 31, – 2026 | 2025 |
|---|---:|---:|
| Revenue | 496,246 | 483,649 |
| Cost of revenue | 412,472 | 381,178 |
| Selling, general and administrative expenses | 72,818 | 78,409 |
| Net loss attributable to common shareholders of Evolent Health, Inc. | -26,632 | -72,250 |
| Net loss margin | -5.4% | -14.9% |
| Loss per share attributable to common shareholders of Evolent Health, Inc. | Basic and diluted | -0.24 | -0.63 |

### Income Statement (For the Three Months Ended March 31, — Evolent Health, Inc. reported the following adjusted results (dollars in thousands, except for per share data):)

| | For the Three Months Ended March 31, – 2026 | 2025 |
|---|---:|---:|
| Adjusted cost of revenue | 411,953 | 380,521 |
| Adjusted selling, general and administrative expenses | 62,226 | 66,268 |
| Adjusted EBITDA | 22,067 | 36,860 |
| Adjusted EBITDA margin | 4.4% | 7.6% |
| Adjusted income (loss) attributable to common shareholders | -2,253 | 7,445 |
| Adjusted income (loss) per share attributable to common shareholders: | Basic | -0.02 | 0.06 |

### Income Statement (For the Three Months Ended March 31, — (unaudited, in thousands, except per share data))

| | For the Three Months Ended March 31, – 2026 | 2025 |
|---|---:|---:|
| Revenue | 496,246 | 483,649 |
| Expenses | Cost of revenue | 412,472 | 381,178 |
| Expenses | Selling, general and administrative expenses | 72,818 | 78,409 |
| Expenses | Depreciation and amortization expenses | 21,555 | 24,058 |
| Expenses | Loss on lease termination |  | 1,906 |
| Expenses | Change in fair value of contingent consideration |  | -280 |
| Expenses | Operating expenses | 506,845 | 485,271 |
| Expenses | Operating loss | -10,599 | -1,622 |
| Expenses | Interest income | 1,014 | 1,274 |
| Expenses | Interest expense | -16,868 | -10,385 |
| Expenses | Loss from equity method investees | -11 | -19 |
| Expenses | Loss on option exercise |  | -52,348 |
| Expenses | Other income (expense), net | 742 | -48 |
| Expenses | Loss before income taxes | -25,722 | -63,148 |
| Expenses | Provision for income taxes | 910 | 1,470 |
| Expenses | Loss before preferred dividends and accretion of Series A Preferred Stock including excise tax | -26,632 | -64,618 |
| Expenses | Dividends and accretion of Series A Preferred Stock including excise tax |  | -7,632 |
| Expenses | Net loss attributable to common shareholders of Evolent Health, Inc. | -26,632 | -72,250 |
| Loss per common share | Basic and diluted | -0.24 | -0.63 |
| Weighted-average common shares outstanding | Basic and diluted | 111,905 | 115,315 |
| Comprehensive loss | Net loss attributable to common shareholders of Evolent Health, Inc. | -26,632 | -72,250 |
| Other comprehensive loss, net of taxes, related to: | Foreign currency translation adjustment | -1,002 | 24 |
| Other comprehensive loss, net of taxes, related to: | Total comprehensive loss attributable to common shareholders of Evolent Health, Inc. | -27,634 | -72,226 |

### Income Statement ((unaudited, in thousands))

| | For the Three Months Ended March 31, – 2026 | 2025 |
|---|---:|---:|
| Cost of revenue | 412,472 | 381,178 |
| Less: | Stock-based compensation | 519 | 657 |
| Less: | Adjusted cost of revenue | 411,953 | 380,521 |
| Reconciliation of Adjusted Selling, General and Administrative Expenses to Selling, General and Administrative Expenses | Selling, general and administrative expenses | 72,818 | 78,409 |
| Less: | Stock-based compensation | 10,130 | 10,424 |
| Less: | Severance costs |  | 1,014 |
| Less: | Transaction-related costs | 462 | 703 |
| Less: | Adjusted selling, general and administrative expenses | 62,226 | 66,268 |

### Income Statement (For the Three Months Ended March 31, — (unaudited, in thousands except MER percentages))

| | For the Three Months Ended March 31, – 2026 | For the Three Months Ended March 31, – 2025 |
|---|---:|---:|
| Revenue | Performance Suite | 323,303 | 303,021 |
| Revenue | Specialty Technology and Services Suite | 80,799 | 82,821 |
| Revenue | Administrative Services | 49,587 | 57,191 |
| Revenue | Cases | 42,557 | 40,616 |
| Revenue | Total revenue | 496,246 | 483,649 |
| Less: | Revenue from Evolent Care Partners |  | 57,799 |
| Less: | Performance Suite revenue less revenue from Evolent Care Partners | 323,303 | 245,222 |
| Less: | Total claims incurred related to our specialty care management services solution | 301,777 | 205,992 |
| Less: | Medical expense ratio | 93.3 | 68 |
| Less: | Medical expense ratio excluding Evolent Care Partners | 93.3 | 84 |

### Income Statement (For the Three Months Ended March 31, — (unaudited, in thousands, except per share data))

| | For the Three Months Ended March 31, – 2026 | 2025 |
|---|---:|---:|
| Net loss attributable to common shareholders of Evolent Health, Inc. | -26,632 | -72,250 |
| Less: | Loss from equity method investees | -11 | -19 |
| Less: | Other income (expense), net | 742 | -48 |
| Less: | Provision for income taxes | -910 | -1,470 |
| Less: | Change in fair value of contingent consideration |  | 280 |
| Less: | Loss on option exercise |  | -52,348 |
| Less: | Purchase accounting adjustments | -12,490 | -13,365 |
| Less: | Loss on lease termination |  | -1,906 |
| Less: | Stock-based compensation expense | -10,649 | -11,081 |
| Less: | Severance costs |  | -1,014 |
| Less: | Transaction-related costs | -462 | -703 |
| Less: | Tax impact (1) | -599 | 1,979 |
| Less: | Adjusted income (loss) attributable to common shareholders | -2,253 | 7,445 |
| Loss per share attributable to common shareholders | Basic | -0.24 | -0.63 |
| Adjusted income (loss) per share attributable to common shareholders | Basic | -0.02 | 0.06 |
| Weighted-average common shares | Basic | 111,905 | 115,315 |

### Balance Sheet (March 31, 2026 — (in thousands, except share data))

| | March 31, 2026 – (unaudited) | December 31, 2025 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 142,028 | 151,856 |
| Current assets: | Restricted cash | 23,977 | 26,134 |
| Current assets: | Accounts receivable, net | 314,158 | 309,861 |
| Current assets: | Prepaid expenses and other current assets | 21,847 | 18,521 |
| Current assets: | Total current assets | 502,010 | 506,372 |
| Current assets: | Restricted cash | 2,739 | 2,706 |
| Current assets: | Investments and equity method investees | 8,955 | 8,966 |
| Current assets: | Property and equipment, net | 81,181 | 80,785 |
| Current assets: | Right-of-use assets - operating | 3,866 | 4,373 |
| Current assets: | Prepaid expenses and other noncurrent assets | 2,250 | 3,078 |
| Current assets: | Contract cost assets | 13,731 | 13,537 |
| Current assets: | Intangible assets, net | 569,682 | 584,937 |
| Current assets: | Goodwill | 694,433 | 694,482 |
| Current assets: | Total assets | 1,878,847 | 1,899,236 |
| Current liabilities: | Accounts payable | 63,007 | 59,776 |
| Current liabilities: | Accrued liabilities | 45,063 | 65,755 |
| Current liabilities: | Operating lease liability - current | 8,779 | 15,343 |
| Current liabilities: | Accrued compensation and employee benefits | 31,007 | 50,987 |
| Current liabilities: | Deferred revenue | 1,417 | 1,203 |
| Current liabilities: | Reserve for claims and performance - based arrangements | 231,962 | 192,196 |
| Current liabilities: | Total current liabilities | 381,235 | 385,260 |
| Current liabilities: | Long-term debt, net | 973,486 | 970,537 |
| Current liabilities: | Other long-term liabilities | 8,091 | 8,012 |
| Current liabilities: | Tax receivables agreement liability | 108,909 | 108,909 |
| Current liabilities: | Operating lease liabilities - noncurrent | 3,160 | 3,818 |
| Current liabilities: | Deferred tax liabilities, net | 7,573 | 7,506 |
| Current liabilities: | Total liabilities | 1,482,454 | 1,484,042 |
| Shareholders' Equity | Class A common stock - $0.01 par value; 750,000,000 shares authorized; 118,449,473 and 117,603,806 shares issued, respectively | 1,185 | 1,176 |
| Shareholders' Equity | Additional paid-in-capital | 1,802,222 | 1,793,398 |
| Shareholders' Equity | Accumulated other comprehensive loss | -3,626 | -2,624 |
| Shareholders' Equity | Retained earnings (accumulated deficit) | -1,341,959 | -1,315,327 |
| Shareholders' Equity | Treasury stock, at cost; 5,971,712 and 5,971,712 shares issued, respectively | -61,429 | -61,429 |
| Shareholders' Equity | Total shareholders’ equity | 396,393 | 415,194 |
| Shareholders' Equity | Total liabilities and shareholders’ equity | 1,878,847 | 1,899,236 |

### Cash Flow (For the Three Months Ended March 31, — (unaudited, in thousands))

| | For the Three Months Ended March 31, – 2026 | For the Three Months Ended March 31, – 2025 |
|---|---:|---:|
| Cash Flows (Used In) Provided by Operating Activities | Loss before preferred dividends and accretion of Series A Preferred Stock | -26,632 | -64,618 |
| Adjustments to reconcile net loss to net cash and restricted cash provided by operating activities: | Change in fair value of contingent consideration |  | -280 |
| Adjustments to reconcile net loss to net cash and restricted cash provided by operating activities: | Loss (gain) from equity method investees | 11 | 19 |
| Adjustments to reconcile net loss to net cash and restricted cash provided by operating activities: | Loss on option exercise |  | 52,348 |
| Adjustments to reconcile net loss to net cash and restricted cash provided by operating activities: | Depreciation and amortization expenses | 21,555 | 24,058 |
| Adjustments to reconcile net loss to net cash and restricted cash provided by operating activities: | Stock-based compensation expense | 10,649 | 11,081 |
| Adjustments to reconcile net loss to net cash and restricted cash provided by operating activities: | Deferred tax benefit | 577 | 295 |
